February 26. 2007 -- New River and Shire received FDA approval of Vyvanse, their abuse-resistant ADHD drug; Bristol-Myers Squibb partnered with Adnexus to develop Adnectin candidates for cancer; Lilly received FDA approval of Cymbalta as a treatment for generalized anxiety disorder and announced a new trial of sepsis drug Xigris; MDS sold its Canadian lab business for $1.325 billion (Canadian); Hollis-Eden showied Neumune was effective in improving survival in irradiated monkeys; Cell Therapeutics said Xyotax produced a major response in 24% of prostate cancer patients; AstraZeneca began a Phase III trial of lung cancer drug Zactima; and Samaritan will distribute Elaprase for Shire in Greece and Cyprus. The Centient Biotech 200™ edged 2 points lower to 4052, a loss of .05%. More details...
